Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 10,330 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Congenital Malformation Clear all
Completed Not applicable Interventional Results available

Evaluating the Efficacy of Pediatric Lipid Screening Alerts

NCT04118348
View directory record Official record
Conditions
Hypercholesterolemia, Hypercholesterolemia, Familial, Hypercholesteremia in Children, Hyperlipidemia in Children
Interventions
Best Practice Alert, Health Maintenance Topic
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
9 Years to 11 Years
Enrollment
13,340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Sep 30, 2026, 5:15 PM EDT
Recruiting No phase listed Observational

Vascular Lab Resource (VLR) Biorepository

NCT05628948
View directory record Official record
Conditions
Cardiovascular Diseases, Metabolic Disease, Peripheral Artery Disease, Carotid Disease, Aneurysmal Disease, Venous Disease, Thrombosis, Lymphedema, Lipedema, Non-Atherosclerotic Chronic Arterial Occlusive Disease, Vasculitis, Fibromuscular Dysplasia, Arterial Dissection, May-Thurner Syndrome, Thoracic Outlet Syndrome, Vasospasm
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
500 participants
Timeline
2019 – 2031
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Sep 30, 2026, 5:15 PM EDT
Completed No phase listed Observational

Natural History and Genetic Studies of Usher Syndrome

NCT00106743
View directory record Official record
Conditions
Retinitis Pigmentosa Syndromic, Congenital Deafness, Usher Syndrome, Retinitis Pigmentosa and Deafness, Retinitis Pigmentosa
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
2 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
2
States / cities
Bethesda, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Sep 30, 2026, 5:15 PM EDT
Active, not recruiting Phase 3 Interventional

RZ358 Treatment for Congenital Hyperinsulinism

NCT06208215
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC, RZ358 (10 mg/kg) or Placebo + SOC, RZ358 (5-10 mg/kg) + SOC
Drug
Lead sponsor
Rezolute
Other
Eligibility
3 Months to 45 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 30, 2026, 5:15 PM EDT
Completed No phase listed Observational

Early Diagnosis of Sickle Acute Chest Syndrome Using a Combination of Plasma Bimarkers and Chest Imaging

NCT03478917
View directory record Official record
Conditions
Sickle Cell Disease (SCD)
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 85 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Sep 30, 2026, 5:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Quality by Maintaining Accurate Problems in the EHR

NCT02596087
View directory record Official record
Conditions
Asthma, Atrial Fibrillation, Chronic Obstructive Pulmonary Disease, Coronary Artery Disease, Congestive Heart Failure, Hyperlipidemia, Hypertension, Myocardial Infarction, Sickle Cell Disease, Sleep Apnea, Smoking, Stroke, Tuberculosis
Interventions
Problem List Suggestion
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2,386 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Portland, Oregon • Camp Hill, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 30, 2026, 5:15 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program

NCT05368038
View directory record Official record
Conditions
Acid Sphingomyelinase Deficiency, Ceroid Lipofuscinosis, Neuronal, 2, Cerebrotendinous Xanthomatosis, Fabry Disease, GM1 Gangliosidosis, Gaucher Disease, Lysosomal Acid Lipase Deficiency, Metachromatic Leukodystrophy, Mucopolysaccharidosis II, Mucopolysaccharidosis III-B, Mucopolysaccharidosis IV A, Mucopolysaccharidosis VI, Mucopolysaccharidosis VII, Niemann-Pick Disease, Type C
Interventions
Confirmatory Testing
Diagnostic Test
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
Up to 4 Weeks
Enrollment
100,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2029
U.S. locations
9
States / cities
Brooklyn, New York • Manhasset, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 30, 2026, 5:15 PM EDT
Active, not recruiting No phase listed Observational

Genetic and Physical Study of Childhood Nerve and Muscle Disorders

NCT01568658
View directory record Official record
Conditions
Muscular Dystrophies, Muscle Myopathies, Hereditary Spastic Paraplegias, Inherited Neuropathies, Inherited Neuromuscular Conditions
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
1 Day to 100 Years
Enrollment
2,586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 30, 2026, 5:15 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Defining the Brain Phenotype of Children With Williams Syndrome

NCT01132885
View directory record Official record
Conditions
Williams Syndrome, Duplication
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
5 Years and older
Enrollment
415 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 30, 2026, 5:15 PM EDT
Completed Phase 2 Interventional Results available

Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency

NCT01213043
View directory record Official record
Conditions
Emphysema, Alpha 1-antitrypsin Deficiency (AATD)
Interventions
Prolastin-C, 60 mg/kg, Prolastin-C, 120 mg/kg
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Gainesville, Florida • Miami, Florida • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Sep 30, 2026, 5:15 PM EDT
Active, not recruiting Not applicable Interventional

Anterior Cervical Disectomy And Fusion Using The Tritanium® C Anterior Cervical Cage For One Or Two-Levels

NCT04214535
View directory record Official record
Conditions
Cervical Disc Herniation, Cervical Disc Degeneration, Degenerative Disc Disease
Interventions
Tritanium C Anterior Cervical Cage
Device
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Sep 30, 2026, 5:15 PM EDT
Completed Phase 2 Interventional

A Study of RO4917523 in Patients With Fragile X Syndrome

NCT01517698
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
Placebo, RO4917523 0.5 mg, RO4917523 1.5 mg
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
14 Years to 50 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
20
States / cities
Phoenix, Arizona • Long Beach, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Sep 30, 2026, 5:15 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Ketamine Infusion for Acute Sickle Cell Crisis in the Emergency Department

NCT02417298
View directory record Official record
Conditions
Pain, Sickle Cell Disorder
Interventions
Normal saline, Ketamine
Drug
Lead sponsor
Billy Sin
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Sep 30, 2026, 5:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Trial of Bilateral Sagittal Split Osteotomy Induced Paresthesia Using Ultrasonic vs. Reciprocating Saw Instrumentation

NCT05205616
View directory record Official record
Conditions
Surgical Complication, Paresthesia, Fracture, Nerve Injury, Nerve Entrapments, Mandibular Nerve Injuries, Mandibular Hypoplasia, Mandibular Retrognathism, Mandibular Hyperplasia, Mandibular Prognathism
Interventions
Sonopet ultrasonic saw, Reciprocating saw
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 30, 2026, 5:15 PM EDT
Terminated Phase 4 Interventional

Antibody Production in Immune Disorders

NCT00023504
View directory record Official record
Conditions
Primary Immune Deficiency
Interventions
Pneumovax, Rabavert, Prevnar, Tetanus diphtheria toxoid
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Sep 30, 2026, 5:15 PM EDT
Recruiting Phase 2 Interventional

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

NCT07175038
View directory record Official record
Conditions
Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease
Interventions
ROC-101
Drug
Lead sponsor
AllRock Bio, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
Phoenix, Arizona • Rancho Cordova, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 30, 2026, 5:15 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Comparing the Inflammation, Maldigestion and Symptoms Due to Commercial Milk and A2 Milk

NCT05660278
View directory record Official record
Conditions
Lactose Intolerance
Interventions
Milk containing A1 and A2 beta-casein, Milk containing only A2 beta-casein
Other
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Sep 30, 2026, 5:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of FTX-6058

NCT04586985
View directory record Official record
Conditions
Healthy Adult Subjects, Sickle Cell Disease
Interventions
FTX-6058/placebo oral capsule(s), FTX-6058 - Two Dosing Periods, FTX-6058 / Midazolam Syrup
Drug
Lead sponsor
Fulcrum Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Sep 30, 2026, 5:15 PM EDT
Recruiting Phase 2 Interventional

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

NCT01962415
View directory record Official record
Conditions
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions, Systemic Juvenile Idiopathic Arthritis (sJIA), Juvenile Rheumatoid Arthritis (JRA)
Interventions
Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa
Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
2 Months to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 30, 2026, 5:15 PM EDT
Not listed Not applicable Interventional

Targeting Surgeons' Decision-Making for Cleft Lip Surgery

NCT03537976
View directory record Official record
Conditions
Cleft Palate, Cleft Lip
Interventions
Static Images and Facial Videos
Other
Lead sponsor
Tufts University
Other
Eligibility
0 Months to 21 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Sep 30, 2026, 5:15 PM EDT
Completed Phase 3 Interventional

A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis

NCT05571943
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Difamilast
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
2 Years and older
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
63
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Sep 30, 2026, 5:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

NCT03989115
View directory record Official record
Conditions
Solid Tumor
Interventions
RMC-4630, Cobimetinib, Drug: Osimertinib
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Sep 30, 2026, 5:15 PM EDT
Completed No phase listed Observational

Outpatient Office Based Endovascular Procedures

NCT04054440
View directory record Official record
Conditions
Chronic Venous Insufficiency, Peripheral Arterial Disease, Dialysis Access Malfunction, Arterio-venous Fistula, Thoracic Outlet Syndrome, Vertebral Artery Insufficiency, Varicose Veins
Interventions
Not listed
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
26,000 participants
Timeline
2014 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 30, 2026, 5:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL

NCT01544348
View directory record Official record
Conditions
Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
Interventions
Placebo, Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous, MEDI4212 60 mg Subcutaneous, MEDI4212 150 mg Subcutaneous, MEDI4212 300 mg Subcutaneous, MEDI4212 300 mg Intravenous
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
295 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
7
States / cities
Cypress, California • Glendale, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Sep 30, 2026, 5:15 PM EDT